SHEZF (Shenzhen Hepalink Pharmaceutical Group Co) Interest Expense: $-8.8 Mil (TTM As of Mar. 2026)


SHEZF Shenzhen Hepalink Pharmaceutical Group Co Ltd SHEZF
69 GF Score
Price $0.47
GF Value $0.57
! 7 Warning Signs
View Full Analysis

What is Shenzhen Hepalink Pharmaceutical Group Co Interest Expense?

Shenzhen Hepalink Pharmaceutical Group Co SHEZF 69 Interest Expense is $-8.8 Mil as of Mar. 2026. GuruFocus rates SHEZF with a GF Score™ of 69/100 and a GF Value™ of $0.57. The stock has 7 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Shenzhen Hepalink Pharmaceutical Group Co's interest expense for the three months ended in Mar. 2026 was $ -1.9 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was $-8.8 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Shenzhen Hepalink Pharmaceutical Group Co's Operating Income for the three months ended in Mar. 2026 was $ 29.4 Mil. Shenzhen Hepalink Pharmaceutical Group Co's Interest Expense for the three months ended in Mar. 2026 was $ -1.9 Mil. Shenzhen Hepalink Pharmaceutical Group Co's Interest Coverage for the quarter that ended in Mar. 2026 was 15.54. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Shenzhen Hepalink Pharmaceutical Group Co  (OTCPK:SHEZF) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Shenzhen Hepalink Pharmaceutical Group Co's Interest Expense for the three months ended in Mar. 2026 was $-1.9 Mil. Its Operating Income for the three months ended in Mar. 2026 was $29.4 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was $9.3 Mil.

Shenzhen Hepalink Pharmaceutical Group Co's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Interest Coverage=-1* Operating Income (Q: Mar. 2026 )/Interest Expense (Q: Mar. 2026 )
=-1*29.428/-1.894
=15.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Shenzhen Hepalink Pharmaceutical Group Co Interest Expense Historical Data

* Premium members only.

The historical data trend for Shenzhen Hepalink Pharmaceutical Group Co's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shenzhen Hepalink Pharmaceutical Group Co Interest Expense Chart

Shenzhen Hepalink Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -31.66 -33.74 -31.26 -19.39 -10.14

Shenzhen Hepalink Pharmaceutical Group Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.10 -2.44 -2.13 -2.32 -1.89
SHEZF
69GF Score
Shenzhen Hepalink Pharmaceutical Group Co Ltd SHEZF
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shenzhen Hepalink Pharmaceutical Group Co Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of $-8.8 Mil mean?
Shenzhen Hepalink Pharmaceutical Group Co (SHEZF) has a Interest Expense of $-8.8 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Shenzhen Hepalink Pharmaceutical Group Co and its competitors.
Is Shenzhen Hepalink Pharmaceutical Group Co's Interest Expense too high?
Shenzhen Hepalink Pharmaceutical Group Co's current Interest Expense is $-8.8 Mil. Overall, Shenzhen Hepalink Pharmaceutical Group Co has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Shenzhen Hepalink Pharmaceutical Group Co's Interest Expense compare to ZTS and UTHR?
Shenzhen Hepalink Pharmaceutical Group Co's Interest Expense of $-8.8 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Drug Manufacturers company?
A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Shenzhen Hepalink Pharmaceutical Group Co and its competitors. Shenzhen Hepalink Pharmaceutical Group Co's current Interest Expense is $-8.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shenzhen Hepalink Pharmaceutical Group Co stock overvalued right now?
Shenzhen Hepalink Pharmaceutical Group Co (SHEZF) has a current Interest Expense of $-8.8 Mil. The stock's GF Value™ is $0.57, compared to a current price of $0.47 — trading 17.6% below its estimated fair value. The current Interest Expense is $-8.8 Mil. Shenzhen Hepalink Pharmaceutical Group Co's overall GF Score™ is 69/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Shenzhen Hepalink Pharmaceutical Group Co (SHEZF), the current Interest Expense is $-8.8 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shenzhen Hepalink Pharmaceutical Group Co (SHEZF) Overvalued in 2026?

Based on GuruFocus' analysis, Shenzhen Hepalink Pharmaceutical Group Co stock appears to be undervalued. The current stock price of $0.47 is trading 17.6% below its estimated GF Value™ of $0.57.

Key valuation signals for SHEZF:

  • Interest Expense: $-8.8 Mil
  • GF Value™: $0.57 vs. price of $0.47 (17.6% below fair value)
  • GF Score™: 69/100 with 7 warning signs

No single metric tells the full story. See the SHEZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shenzhen Hepalink Pharmaceutical Group Co Business Description

Other Exchanges 09989:Hong Kong002399:China
Address No. 21 Langshan Road, Songping Mountain, Guangdong Province, Nanshan District, Shenzhen, CHN, 518057
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company. Along with its subsidiary, it is engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading, and biopharmaceutical research and development in Asia, Europe, North America, and Australia, and investment business in Asia and North America. The Group mainly operates three main business segments, including the Finished dose pharmaceutical products; Active pharmaceutical ingredients; CDMO business; and Others. The geographical presence of the company is in Hong Kong, the United States of America, Europe, Mainland China, and Other countries. The majority of the company's revenue comes from Europe and the USA.
69GF Score

Get the complete analysis for SHEZF

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.47
Price
$0.57
GF Value